Peruvoside
From Wikipedia, the free encyclopedia
 |
|
|
Peruvoside
|
|
| Systematic (IUPAC) name | |
| (3S,5R,10R,13R,14S,17R)-3-[(2S,5R)-3,5-dihydroxy-4-methoxy-6-methyloxan-2-yl]oxy-14-hydroxy-13-methyl-17-(5-oxo-2H-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthrene-10-carbaldehyde | |
| Identifiers | |
| CAS number | |
| ATC code | C01 |
| PubChem | |
| Chemical data | |
| Formula | C30H44O9 |
| Mol. mass | 548.665 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Peruvoside (or cannogenin thevetoside) is a cardiac glycoside.[1]
[edit] References
- ^ Peruvoside and Other Cardiotonic Glycoside[s] of Thevetia nereifolia; Chemical, Pharmacological, and Clinical Studies. Arora, R. B.; Rangaswami, S. (1972), Publisher: (Thomson, New Delhi, India)
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
|
||||||||||||||
